



Supplementary Figure 1. (A) The anti-RBD IgG binding antibody and (B) neutralizing antibody levels before (baseline) and after the first (post-dose 1) and second (post-dose 2) vaccination of each COVID-19 mRNA vaccine, BNT162b2 and mRNA-1273, in the control, adjuvant, and palliative groups. The levels are on the logarithmic scale and indicated as a scatter dot-plot with median and interquartile ranges. The dotted lines are the threshold for positivity suggested by the manufacturers for conversion to the World Health Organization's standard units (A: 7.1 BAU/mL, B: 28.4 IU/mL). *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$.